First Generic Lenacapavir Lands FDA Tentative Approval at $40 a Year

The FDA granted Dr. Reddy's Laboratories tentative approval for the first generic version of lenacapavir, the twice-yearly injectable used for HIV prevention and treatment. Tentative approval means the formulation cleared every statutory bar on safety, quality and bioequivalence, but it cannot be sold in the US while patents on Gilead Sciences' branded product hold. Under the PEPFAR framework, applications filed through the 505(b)(2) or 505(j) pathways with Paragraph III patent certifications can still be procured and distributed in high-prevalence, resource-limited countries.

Dr. Reddy's got there in 16 months — not the decade generics usually take. The company folded lenacapavir's prevention and treatment indications into a single application under the 505(b)(2) pathway, with technical and financial backing from Unitaid, Wits RHI and the Clinton Health Access Initiative, and won priority review that compressed a multi-year evaluation into six months. “Getting a generic approved just 16 months after the originator, rather than a decade later, shows what's possible when we prioritize access from the start,” CHAI CEO Neil Buddy Shah said. “This should be the new standard for global health.”

The price tag is the headline number: $40 per person per year under a landmark licensing framework, against the branded product's $28,218 annual list price set by Gilead. First supplies of the generic injection are projected to hit designated international markets before the end of 2026, with broader distribution following in 2027. Demand is already proven — more than 125,000 people across 10 African countries started on the originator before a generic existed.

Access still stops at a border. Gilead's voluntary licensing deals with six generic manufacturers cover supply rights for 120 low- and middle-income nations, but explicitly shut out 26 middle-income countries and territories, including several battling growing HIV epidemics, according to Drug Topics. Patients there miss the $40 option entirely.

For pharmacists, the shift is about confidence in the switch. FDA-cleared generics must match on active ingredient and bioequivalence, with absorption varying by an average of just 3.5% versus brand-name drugs. That matters because prescription abandonment runs 266% higher for brand-name products on copay burden, and pharmacist-led antiretroviral stewardship has cut inpatient ARV error rates from 17% to 2% of hospital days. “Any pharmacist can now change and make an appropriate transition for these patients on their home regimen and can appropriately dose it according to their renal function, liver function,” said Nicholas Rebold, PharmD, of Howard University College of Pharmacy. “It's really treating these antiretroviral drugs just like we do every other disease state, every other drug.”